MIRA INFORM REPORT
|
Report Date : |
21.03.2012 |
|
|
|
|
Tel. No.: |
00852-2152-1317 |
|
Fax No.: |
008852-2116-3420 |
IDENTIFICATION DETAILS
|
Name : |
FRESENIUS
KABI ASIA PACIFIC
LTD. |
|
|
|
|
Registered Office : |
Room 5012-5036, 50/F., Sun Hung Kai Centre, 30 Harbour
Road, Wanchai |
|
|
|
|
Country : |
Hong Kong |
|
|
|
|
Date of Incorporation : |
12.02.2001 |
|
|
|
|
Com. Reg. No.: |
31582695 |
|
|
|
|
Legal Form : |
Private Limited Company. |
|
|
|
|
Line of Business : |
Importer, Exporter and Wholesaler of Medical equipment such as for infusion therapy and clinical nutrition, etc |
|
|
|
|
No. of Employees
: |
30. (Including
affiliates in Hong Kong) |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Good |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30th, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
Hong Kong |
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
FRESENIUS KABI ASIA PACIFIC LTD.
Room 5012-5036, 50/F., Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hong Kong.
PHONE: 2152 1300, 2116 2683
FAX: 2877 8943, 2116 3420
E-MAIL: asia-pacific@fresenius-kabi.com
ulf.jansson@fresenius-kabi.com
Managing Director: Mr. Mats Christer Henriksson
Incorporated on: 12th February, 2001.
Organization: Private Limited Company.
Capital: Nominal: HK$100,000.00
Issued: HK$1,000.00
Business Category: Medical Service Organization.
Group Sales:- (Year ended 31-12-2011)
€16,522 million (Fresenius Group)
€ 3,964 million (Fresenius Kabi Division)
Company Employees: 30. (Including affiliates in Hong Kong)
Group Employees:- (As at 31-12-2011)
149,351. (Fresenius Group)
24,106. (Fresenius Kabi Division)
Main Dealing Banker: The Hongkong & Shanghai Banking Corp. Ltd., Hong Kong.
Banking Relation: Good.
Registered Head
Office:-
Room 5012-5036, 50/F., Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hong Kong.
Immediate Holding
Company:-
Fresenius Kabi AG
Else-Kröener-Strasße 1, 61352 Bad, Hamburg, Germany.
[Tel: 49 (0) 6172-686-0]
Ultimate Holding
Company:-
Fresenius SE & Co. KGaA
Else-Kröener-Strasße 1, 61352 Bad, Hamburg, Germany.
[Tel: 49 (0) 6172-608-0; Fax: 49 (0) 6172-608-2294]
Affiliated Companies:-
Fresenius Group of Companies
APP Pharmaceuticals Inc., USA.
Beijing Fresenius Kabi Pharmaceutical Co.
Ltd., China.
Calea France S.A.S., France.
Calea Ltd., Canada.
Calea UK Ltd., UK.
Fresenius HemoCare Austria GmbH, Austria.
Fresenius HemoCare Brazil Ltda., Brazil.
Fresenius HemoCare CZ s.r.o., Czech Republic.
Fresenius HemoCare GmbH, Germany.
Fresenius HemoCare Italia S.r.l., Italy.
Fresenius HemoCare Netherlands B.V.,
Netherlands.
Fresenius Kabi (China) Co. Ltd., China.
Fresenius Kabi (Schweiz) AG, Switzerland.
Fresenius Kabi (Singapore) Pte. Ltd.,
Singapore.
Fresenius Kabi (Thailand) Ltd., Thailand.
Fresenius Kabi AB, Finland.
Fresenius Kabi AB, Sweden.
Fresenius Kabi AG, Germany.
Fresenius Kabi Anti-Infectives S.r.l., Italy.
Fresenius Kabi Argentina SA, Argentina.
Fresenius Kabi Asia Pacific Ltd., Vietnam.
Fresenius Kabi Australia Pty. Ltd.,
Australia.
Fresenius Kabi Austria GmbH, Austria.
Fresenius Kabi Brazil Ltda., Brazil.
Fresenius Kabi Chile Ltda., Chile.
Fresenius Kabi Colombia S.A.S., Colombia.
Fresenius Kabi Denmark, Denmark.
Fresenius Kabi Deutschland GmbH, Germany.
Fresenius Kabi EOOD, Bulgaria.
Fresenius Kabi España S.A., Spain.
Fresenius Kabi France S.A.S, France.
Fresenius Kabi Hellas S.A., Greece.
Fresenius Kabi Hong Kong Ltd., Hong Kong.
Fresenius Kabi Hungary Kft., Hungary.
Fresenius Kabi Ilac Sanayi ve Ticaret Ltd.
Sirketi, Turkey.
Fresenius Kabi India Private Ltd., India.
Fresenius Kabi Ireland, Ireland.
Fresenius Kabi Italia S.p.A., Italy.
Fresenius Kabi Italia S.r.l., Italy.
Fresenius Kabi Japan K.K., Japan.
Fresenius Kabi Korea Ltd., South Korea.
Fresenius Kabi Ltd., UK.
Fresenius Kabi Malaysia Sdn. Bhd, Malaysia.
Fresenius Kabi México S.A. de C.V., Mexico.
Fresenius Kabi N.V., Belgium.
Fresenius Kabi Nederland B.V., Netherlands.
Fresenius Kabi New Zealand Ltd., New Zealand.
Fresenius Kabi Norge A/S, Norway.
Fresenius Kabi North America, USA.
Fresenius Kabi Oncology Ltd., India.
Fresenius Kabi Pharma Portugal Lda.,
Portugal.
Fresenius Kabi Pharmaceuticals Holding Inc.,
USA.
Fresenius Kabi Philippines Inc., Philippines.
Fresenius Kabi Polska Sp. z.o.o., Poland.
Fresenius Kabi Romania S.R.L., Romania.
Fresenius Kabi s.r.o., Czech Republic.
Fresenius Kabi Scientific Office, Egypt.
Fresenius Kabi South Africa (Pty) Ltd., South
Africa.
Fresenius Kabi Taiwan Ltd., Taiwan.
Fresenius Kabi, France.
Fresenius Kabi, UAE.
Fresenius Vial S.A.S., France.
Hosped GmbH, Germany.
Labesfal – Laboratório Almiro S.A., Portugal.
Laboratorio Sanderson S.A., Chile.
MC Medizintechnik GmbH, Germany.
P.T. Fresenius Kabi Indonesia, Indonesia.
Sino-Swed Pharmaceutical Corporation Ltd.,
China.
etc.
31582695
0746811
Managing Director: Mr. Mats Christer Henriksson
Nominal Share Capital: HK$100,000.00 (Divided into 100,000 shares of HK$1.00 each)
Issued Share Capital: HK$1,000.00
(As per registry
dated 12-02-2012)
|
Name |
|
No. of shares |
|
Fresenius Kabi AG Else-Kröener-Strasße 1,
61352 Bad, Hamburg, Germany. |
|
999 |
|
Fresenius Kabi Deutschland GmbH Else-Kröener-Strasße 1, 61352 Bad, Hamburg,
Germany. |
|
1 |
|
|
|
––––– |
|
|
Total: |
1,000 ==== |
(As per registry
dated 01-03-2012)
|
Name (Nationality) |
Address |
|
Mats Christer HENRIKSSON |
House 42, Cedar Drive, Redhill Peninsula, 18 Pak Pat Shan Road, Tai
Tam, Hong Kong. |
|
Juergen Wolfgang LAUTERBACH |
Flat B, 41/F., Tower 3, 68 Bel-Air Peak Avenue, Bel-Air On the Peak,
Wah Fu, Hong Kong. |
|
Thomas Georg MECHTERSHEIMER |
10 Kananook Avenue, Bayview NSW 2104, Australia. |
(As per registry
dated 12-02-2012)
|
Name |
Address |
Co. No. |
|
Clarson Services Ltd. |
18/F., Edinburgh
Tower, The Landmark, 15 Queen’s Road Central, Hong Kong. |
0582737 |
The subject was incorporated
on 12th February, 2001 as a private limited liability company under the Hong
Kong Companies Ordinance.
Initially the subject was
located Room 5101-5123, 51/F., Sun Hung Kai Centre, 30 Harbour Road, Wanchai,
Hong Kong, moved to Room 5012-5036, 50/F. of the same building in March 2009.
Apart from these, neither
material change nor amendment has been ever traced and noted.
Activities: Importer, Exporter and Wholesaler.
Lines: Medical equipment such as for infusion therapy and clinical nutrition, etc.
Company Employees: 30. (Including affiliates in Hong Kong)
Group Employees:- (As at 31-12-2011)
149,351. (Fresenius Group)
24,106. (Fresenius Kabi Division)
Commodities Imported: Imported from Germany and other European countries.
Markets: China, Hong Kong and other Asian countries.
Group Sales:-
|
Period |
Fresenius Group |
Fresenius Kabi
Division |
|
Year ended 31-12-2007 |
€11,358 million |
€2,030 million |
|
Year ended 31-12-2008 |
€12,336 million |
€2,495 million |
|
Year ended 31-12-2009 |
€14,164 million |
€3,086 million |
|
Year ended 31-12-2010 |
€15,972 million |
€3,672 million |
|
Year ended 31-12-2011 |
€16,522 million |
€3,964 million |
Terms/Sales: As per contracted.
Terms/Buying: On various terms.
German Chamber of Commerce, Hong Kong.
Nominal Share Capital: HK$100,000.00 (Divided into 100,000 shares of HK$1.00 each)
Issued Share Capital: HK$1,000.00
Group Net Income:-
|
Period |
Fresenius Group |
Fresenius Kabi
Division |
|
Year ended 31-12-2007 |
€410 million |
€183 million |
|
Year ended 31-12-2008 |
€450 million |
€200 million |
|
Year ended 31-12-2009 |
€514 million |
€200 million |
|
Year ended 31-12-2010 |
€660 million |
€294 million |
|
Year ended 31-12-2011 |
€770 million |
€354 million |
Profit or Loss: Group made profits in the past years.
Condition: Business remains active and normal.
Facilities: Making active use of general banking facilities.
Payment: So far so good.
Commercial Morality: Good.
Bankers:-
· The Hongkong & Shanghai Banking Corp. Ltd., Hong Kong.
· DZ Bank AG Deutsche Zentral-Genossenschaftsbank, Frankfurt AM Main, Hong Kong Branch.
Standing: Good.
Fresenius Kabi Asia Pacific Ltd. is a wholly-owned subsidiary of Fresenius Kabi AG [FKA] which in turn is owned by Fresenius SE & Co. KGaA [Fresenius], both are Germany-based firms. The latter is a listed firm in Germany.
The subject is a segment of
the Fresenius Group. The Fresenius Group
consists of five business segments, each of which is responsible for its own
business operations worldwide: Fresenius Medical Care, Fresenius Kabi and
Fresenius Helios, Fresenius Vamed and Fresenius Biotech.
The subject is the
Asia-Pacific headquarters for FKA.
Fresenius Group is a global health care company with products and
services for dialysis, the hospital and the medical care of patients at home. Around the world, Fresenius Group had 149,351
employees as at 31st December, 2011, the majority in the United States.
Fresenius Kabi is the leader
in Infusion Therapy and Clinical Nutrition in Europe and in its most important
countries of Latin America and Asia Pacific.
In addition, Fresenius Kabi is active in the field of Transfusion
Technology, supplying blood processing systems as well as blood bags and
filters. Fresenius Kabi provides treatment
and care for critically-ill patients in both the hospital and out-patient
environments. Fresenius Kabi provides
clients with the services of Infusion Therapy, Parenteral Nutrition, Enternal
Nutrition, Infusion Technology, Transfusion Technology, And Ambulatory Care.
Fresenius Kabi employed about
24,106 people worldwide as at December 2011.
It has a global network of over 50 sales and marketing organizations and
35 production sites. Its factory in
Friedberg, Germany, in operation since 1997, is one of the modern European
plants for the production of standard infusion solutions. In 1999, Fresenius Kabi opened a highly
automated production site for parenteral nutrition infusion solutions in
Uppsala, Sweden.
Fresenius Kabi was formed by
combining Fresenius Group’s Pharma division with the infusion solution business
acquired from Pharmacia & Upjohn (Kabi) in 1999. The new company has become Europe’s leader in
the field of nutrition and infusion therapy, offering a comprehensive product
and service portfolio worldwide for hospitals and patients at home.
In 2000, Fresenius Kabi accelerated
its worldwide business expansion by opening up new growth markets in Asia,
Africa and Latin America as well as expanding the service program.
In 2003, the business
segment Fresenius HemoCare was reallocated within the Fresenius Group. It was due to their similar technology
platform, the Infusion Technology and Transfusion Technology Divisions were
combined under one management and assigned to Fresenius Kabi.
In 2004, Fresenius Kabi
strengthened its market positions with acquisitions in South Africa and Czech
Republic as well as with a joint venture in Australia.
In 2005, the Group expanded
the I.V. drug portfolio via acquisition of the Portuguese pharmaceutical
company Labesfal. In the same year,
Fresenius Kabi strengthened product portfolio and production network of medical
devices through the acquisition of the business of Clinico.
The subject is also
marketing Infusion Therapy and Clinical Nutrition in Hong Kong. All of its customers are hospitals or
patients staying at home.
Fresenius Kabi currently is
engaged in launching new products having good quality. In 2010, Fresenius Kabi achieved
above-average growth in sales.
The subject is fully
supported by Fresenius Kabi and its affiliated companies worldwide.
For the year ended 31st
December, 2011, the sales of Fresenius Kabi amounted to €3,964 million, grew by
8.0% comparing with that of €3,672 million in FY 2010. Net income in this division for the year was
€354 million, grew by 20.4% comparing with that of €294 million in FY 2010.
As far as the turnover of
the Group is concerned, for the year ended 31st December, 2011, the sales
of the Group amounted to €16,522 million, grew by 3.4% comparing with that of €15,972
million in FY 2010. Net income for the
year was €770 million, grew by 16.7% comparing with that of €660 million in FY
2010.
On the whole, in view of the
subject’s background and parentage, consider it good for normal business
engagements.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.50.25 |
|
UK Pound |
1 |
Rs.79.76 |
|
Euro |
1 |
Rs.66.52 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.